<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cryptotanshinone (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e>), a major constituent from the roots of Salvia miltiorrhiza (Danshen), is widely used in the treatment of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e>, <z:hpo ids='HP_0001297'>stroke</z:hpo> and less commonly <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Our recent study indicates that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> is a substrate for P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (PgP/MDR1/ABCB1) </plain></SENT>
<SENT sid="2" pm="."><plain>This study has investigated the nature of the brain distribution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> across the brain-blood barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) using several in vitro and in vivo <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A polarized transport of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> was found in rat primary microvascular endothelial cell (RBMVEC) monolayers, with facilitated efflux from the abluminal side to <z:chebi fb="2" ids="8069">luminal</z:chebi> side </plain></SENT>
<SENT sid="4" pm="."><plain>Addition of a PgP (e.g. <z:chebi fb="1" ids="9948">verapamil</z:chebi> and <z:chebi fb="0" ids="28593">quinidine</z:chebi>) or multi-drug resistance protein 1/2 (MRP1/2) inhibitor (e.g. probenecid and MK-571) in both <z:chebi fb="2" ids="8069">luminal</z:chebi> and abluminal sides attenuated the polarized transport </plain></SENT>
<SENT sid="5" pm="."><plain>In a bilateral in situ brain perfusion model, the uptake of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> into the cerebrum increased from 0.52 +/- 0.1% at 1 min to 11.13 +/- 2.36 ml/100 g tissue at 30 min and was significantly greater than that of <z:chebi fb="27" ids="17992">sucrose</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Co-perfusion of a PgP/MDR1 (e.g. <z:chebi fb="1" ids="9948">verapamil</z:chebi>) or MRP1/2 inhibitor (e.g. probenecid) significantly increased the brain distribution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> by 35.1-163.6% </plain></SENT>
<SENT sid="7" pm="."><plain>The brain levels of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> were only about 21% of those in plasma, and were significantly increased when coadministered with <z:chebi fb="1" ids="9948">verapamil</z:chebi> or probenecid in rats </plain></SENT>
<SENT sid="8" pm="."><plain>The brain levels of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> in rats subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and rats treated with <z:chebi fb="0" ids="16675">quinolinic acid</z:chebi> (a neurotoxin) were about 2- to 2.5-fold higher than the control rats </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, the brain levels in mdr1a(-/-) and mrp1(-/-) mice were 10.9- and 1.5-fold higher than those in the <z:mp ids='MP_0002169'>wild-type</z:mp> mice, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Taken collectively, these findings indicate that PgP and Mrp1 limit the brain penetration of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> in rodents, suggesting a possible role of PgP and MRP1 in limiting the brain penetration of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> in patients and causing drug resistance to Danshen therapy and interactions with conventional drugs that are substrates of PgP and MRP1 </plain></SENT>
<SENT sid="11" pm="."><plain>Further studies are needed to explore the role of other drug transporters in restricting the brain penetration of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTS</z:e> and the clinical relevance </plain></SENT>
</text></document>